Search Results
Rucaparib boosts PFS in BRCA-mutated recurrent ovarian cancer
Rucaparib for Recurrent Ovarian Cancer
Dr. Ledermann on Response to Rucaparib in Recurrent Ovarian Cancer
Cediranib plus olaparib significantly increases PFS in recurrent ovarian cancer
The Clinical Activity of Rucaparib in Patients With Ovarian Cancer
Cediranib plus olaparib increases progression-free survival in recurrent ovarian cancer
Platinum-Sensitive Relapsed Ovarian Cancer: Rucaparib
Precision Medicine for Ovarian Cancer (2021)
Rucaparib and ARIEL3 – positive results from the Phase 3 trial in ovarian cancer patients
SGO 2021 Annual Meeting: Rucaparib vs. Chemotherapy in Ovarian Cancer
SOLO-1: Olaparib or placebo for patients with newly diagnosed BRCA-mutated advanced ovarian cancer
Rucaparib Explored for High-Risk Ovarian Cancer
